Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 update outlining key pipeline developments and clinical milestones. The company plans to expand its oncology portfolio through the proposed acquisition of worldwide rights to CL-741, an oral c-MET kinase inhibitor currently ready for Phase 1 trials. CL-741, developed by Celyn Therapeutics, targets EGFR-mutated lung cancer and other cancers. This candidate would complement Kairos Pharma's existing pipeline, which includes ENV-105, KROS-201, KROS-102, and ENV-205.
Looking ahead, Kairos Pharma expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings, and pursue pharmaceutical collaborations. The company also noted it has secured more than $8 million in non-dilutive funding to support development of its preclinical and clinical programs. The full press release is available at https://ibn.fm/WuBOf.
ENV-105, the company's lead candidate, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. These trials address significant unmet medical needs, though ENV-105 has not yet been approved as safe or effective by the U.S. Food and Drug Administration or any other comparable foreign regulator.
Kairos Pharma, based in Los Angeles, California, specializes in oncology therapeutics, using structural biology to overcome drug resistance and immune suppression in cancer. The company's pipeline reflects a strategic focus on addressing key drivers of cancer progression and treatment resistance. The mid-year update highlights progress across multiple fronts, including the potential addition of CL-741, which could broaden the company's reach in targeted therapies for lung cancer and other malignancies.
The announcement underscores Kairos Pharma's commitment to advancing its clinical programs and expanding its portfolio through strategic acquisitions and collaborations. With non-dilutive funding secured, the company is positioned to move forward with its preclinical and clinical development plans. Investors and stakeholders can find the latest news and updates on KAPA at https://ibn.fm/KAPA.
This update provides a clear picture of Kairos Pharma's near-term priorities and the potential impact of its pipeline on cancer treatment. As the company advances its clinical trials and explores new partnerships, it remains focused on addressing critical needs in oncology.
